Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer’s disease: a systematic review and network meta-analysis of randomized controlled trials

Comparative the efficacy and safety of Gosuranemab, Semorinemab, Tilavonemab, and Zagotenemab in patients with Alzheimer’s disease: a systematic review and network meta-analysis of randomized controlled trials

ObjectiveThe aim of this study was to compare the efficacy and safety of anti-tau protein monoclonal antibodies for Alzheimer’s disease (AD). Tau protein aggregation, a key pathological feature of AD, is closely associated with neurodegeneration and cognitive decline. Targeting tau protein has emerg...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenting Cai, Hui Zhang, Yan Wu, Yao Yao, Jinping Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Aging Neuroscience
Subjects:
anti-tau protein monoclonal antibodies
Alzheimer’s disease
network meta-analysis
randomized controlled trials
efficacy
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fnagi.2024.1465871/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items